Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma

Abstract

In consideration of its significant activity, the role of FLU needs to be further evaluated in the management of pretreated and untreated patients with LG-NHL.

Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia

“…8,9,11,[13][14][15][16] for younger patients, particularly those with refractory or recurrent disease, a more aggressive approach to treatment can be justified.…”

“…[1][2][3][4][5] Although clinical remission can be achieved with standard [6][7][8][9] and newer [10][11][12][13][14] therapies, prolonged freedom from recurrence has not been demonstrated for patients with advanced stage, making death from disease almost inevitable. 8,9,11,[13][14][15][16] for younger patients, particularly those with refractory or recurrent disease, a more aggressive approach to treatment can be justified. [17][18][19][20] High-dose therapy with allogeneic stem cell support is an attractive option for such patients, where marrow involvement is common and the occurrence of a graftversus-leukemia/lymphoma (GVL) effect [21][22][23][24][25][26] may contribute to the achievement of long-term disease control.…”

Fludarabine Combination Regimen Severely Affected Peripheral Blood Stem Cell Mobilization

“…Fludarabine-containing regimens have been reported to be effective in the treatment of B cell chronic lymphocytic leukemia (B-CLL) and low-grade non-Hodgkin’s lymphomas (LG-NHL) [1, 2]either as first-line treatment or as salvage therapy. However, some reports focused their attention on the possibility that fludarabine may affect peripheral blood stem cell (PBSC) yields in B-CLL and other disorders [3, 4, 5].…”

Prolonged follow‐up after initial therapy with 2‐chlorodeoxyadenosine in patients with indolent non‐Hodgkin lymphoma

“…[4][5][6][7][8][9] These results also compare favorably with front-line fludarabine in indolent NHL, in which OR rates from 62% to 84% and CR rates from 15% to 47% have been reported. [33][34][35][36][37] Although the median remission duration in this trial was only 1.9 years, 6 patients have ongoing responses that range from 5.9 years to 11 years. These patients did have fewer adverse prognostic features at the time of study entry, and 3 of these 6 patients had SLL, suggesting that further evaluation of 2-CdA in this NHL subtype may be warranted.…”